Accessibility Menu

Starling Oncology(NASDAQ) STLN

Market Cap$625.89MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-35%
5 Year-37%
1 Year+53%
1 Month-0%
$6.49
+3.67%
+0.23Today
Starling Oncology last closing stock price
MetricPriceDate
Last closeUSD 6.262026-08-13
Starling Oncology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+25.45%USD 4.992026-08-06
1 month-0.32%USD 6.282026-07-14
3 month+57.29%USD 3.982026-05-15
Year to date+75.84%USD 3.562025-12-31
1 year+52.68%USD 4.102025-08-13
3 year+627.82%USD 0.862023-08-14
5 year-37.02%USD 9.942021-08-13
Since inception-35.46%USD 9.702020-06-04

Starling Oncology Financials at a Glance

Market Cap

$625.89MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$587.24M

Net Income (TTM)

-$36.29M

EPS (TTM)

-$0.31

P/E Ratio

-20.51

Dividend

$0.00

Beta (Volatility)

1.15 (Average)

Price

$6.49

Volume

399,921.793

Open

$6.25

Previous Close

$6.26

Daily Range

$6.25 - $6.54

52-Week Range

$2.32 - $7.05

Estimated Earnings Date

Aug 6, 2026

STLN News

Getty - surprised interested amazed wow glasses

A Mysterious Stock Has Rallied Over 950% This Year. Here's 1 Key Reason Why Investors Are Turning Bullish

Selena MaranjianNov 21, 2025
GettyImages-2223908328-1518x800-4a8ddb9

This Healthcare Stock Is Up 1,000%, Outpacing Nvidia, Tesla, and Apple Combined

Lawrence Rothman, CFAOct 21, 2025
Foolcom-Featured.png

Oncology Institute Sales Jump 22 Percent

Motley Fool Markets TeamAug 13, 2025
featured-earnings-leadership-highlights.png

The Oncology Institute Q2 Revenue Surges

Motley Fool Markets TeamAug 13, 2025
GettyImages-592647720-601x370-8b7e932.jpg

Oncology Institute Delivers a Mixed Q3

Motley Fool Markets TeamNov 13, 2024

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Starling Oncology

The Oncology Institute helps adults and seniors manage cancer care. It provides doctor visits, cancer drugs, and support programs. Patients get treatment, medication, and help navigating complex health systems.

What’s in the TOI Toolbox?

  • Physician Services (47%): Cancer doctor visits, chemotherapy, and radiation for adult and senior patients.
  • Dispensary (52%): In-house pharmacy for oral and injectable cancer drugs, both in clinics and by mail.
  • Clinical Trials & Other (1%): Access to research studies, palliative care, and outpatient stem cell transplants.
  • Infusion Services: On-site delivery of cancer drugs through intravenous (IV) infusions.
  • Patient Support: Help with care coordination, insurance, and navigating treatment options.

Growth Moves: The TOI Expansion Playbook

  • Expanded to 66 clinics across five U.S. states by 2025.
  • Entered a profit-sharing partnership with Helios CR, Inc. for clinical trials in 2025.
  • Launched cost reduction initiatives in 2025, and announced plans to pilot AI for insurance approvals.
  • Raised $16.5 million in a private placement in March 2025.
  • Established an at-the-market equity offering facility for up to $15 million in 2025.

Why TOI Isn’t Just Another Clinic

TOI integrates direct cancer care with cost management for patients and insurers. Its in-house pharmacy and coordinated care model streamline treatment and reduce administrative hurdles. The company’s focus on value-based contracts and automation supports operational efficiency.

Five Things You Need to Know

  • Revenue was $120 million in Q2 2025, up 21.5% year-on-year.
  • Dispensary segment led with 52% of Q2 2025 revenue, up 40.8% year-on-year.
  • Operating loss improved to $11 million in Q2 2025, from $16 million in Q2 2024.
  • Net cash used in operations was $15 million for the first half of 2025, down from $32 million.
  • TOI had $30 million in cash and $86 million in debt as of June 2025.

Bottom Line

TOI has grown by expanding clinics, pharmacy services, and research partnerships. The company continues to adapt its model to balance growth and cost control.

AI Generated • Apr 16, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

641

CEO

Daniel Virnich, MD, MBA

Website

www.theoncologyinstitute.com

Headquarters

Cerritos, CA 90703, US

STLN Financials

Key Financial Metrics (TTM)

Gross Margin

15.69%

Operating Margin

-4.44%

Net Income Margin

-6.18%

Return on Equity

209.81%

Return on Capital

-41.02%

Return on Assets

-20.36%

Earnings Yield

-4.88%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$625.89MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

99.98M

Volume

399.92K

Avg. Volume

1.94M

Financials (TTM)

Gross Profit

$92.17M

Operating Income

-$26.09M

EBITDA

-$21.86M

Operating Cash Flow

$328.00K

Capital Expenditure

-$3.61M

Free Cash Flow

-$3.29M

Cash & ST Invst.

$41.09M

Total Debt

$104.48M

Starling Oncology Performance Analysis

Starling Oncology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 252,483,00024.4%
20232023-12-31USD 324,239,00028.4%
20242024-12-31USD 393,412,00021.3%
20252025-12-31USD 502,729,00027.8%
Starling Oncology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-313.9%
Q12026-03-313.9%
Q22026-06-309.4%
Starling Oncology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.2127.7%
20232023-12-31USD -0.92336.8%
20242024-12-31USD -0.71-23.3%
20252025-12-31USD -0.54-22.9%
Starling Oncology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-3157.1%
Q12026-03-3166.7%
Q22026-06-30-300.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$161.28M

N/A

Gross Profit

$27.17M

N/A

Gross Margin

16.84%

N/A

Market Cap

$625.89MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

-$9.79M

N/A

EBITDA

-$6.09M

N/A

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$41.09M

N/A

Total Debt

$104.48M

N/A

Accounts Receivable

$66.71M

N/A

Inventory

$20.01M

N/A

Long Term Debt

$97.25M

N/A

Short Term Debt

$7.23M

N/A

Return on Assets

-20.36%

N/A

Return on Invested Capital

-31.32%

N/A

Free Cash Flow

$11.03M

N/A

Operating Cash Flow

$11.94M

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,794.24+0.01%
^DJIDJI
$53,765.45-0.00%
^IXICNASDAQ
$26,793.14+0.01%
BTCBitcoin
$63,131.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.37+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.60-0.00%
INTCIntel
$103.04-0.01%
ONDSOndas
$9.47+0.06%

Questions About STLN

What is the current price of Starling Oncology?

Starling Oncology is trading at $6.49 per share.

What is the 52-week range for Starling Oncology?

Over the past 52 weeks, Starling Oncology has traded between $2.32 and $7.05.

How much debt does Starling Oncology have?

As of the most recent reporting period, Starling Oncology reported total debt of $104.48M.

How much cash does Starling Oncology have on hand?

Starling Oncology reported $41.09M in cash and cash equivalents in its most recent financial results.

What is Starling Oncology’s dividend yield?

Starling Oncology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services